$NVS news
The latest NVS stock news: headlines, filings, AI summaries and sentiment for $NVS, updated around the clock.
- Novartis Reports Long-Term Efficacy for Ianalumab in Sjögren’s Disease Patients
- Novartis to Halt Development of Ionis-Derived Heart Disease Therapy Following Clinical Trial Failure
- Genmab Reports Strong Q3 2026 Growth Driven by DARZALEX and EPKINLY Sales
- Novartis Shares Decline Following Safety Concerns Regarding Zolgensma Gene Therapy
- REGENXBIO Reports Q3 2026 Financial Results Amid Patent Expirations and Litigation Settlement
- Nanoscope Therapeutics Appoints Damon Daulerio as Executive Director of Regulatory Affairs
- Novartis Raises 2026 Core Operating Income Guidance Following Sales Growth
- Genmab Shares Double Following Three Successful Phase 3 Cancer Drug Trials
- Corporations Report Tangible Financial Gains from Artificial Intelligence Investments
- Deutsche Bank Downgrades Novartis to Sell Following Mixed Q3 Results
- Novartis Faces Future Patent Cliffs Despite Optimism for Remibrutinib
- KKR Acquires 49% Stake in Alexandria Real Estate Equities' San Diego Life Science Campus for $475 Million
- Anthropic's Complex Governance Structure Limits Public Shareholder Control Ahead of IPO
- Novartis Reports Q3 2026 Growth Driven by Priority Brands Amid Generic Competition
- Novartis Reports Q3 Earnings Beat and Upgrades Full-Year Core Operating Income Outlook
- Celcuity Reports Improved Progression-Free Survival with Revtorpyk in Phase 3 Breast Cancer Trial
- Anthropic Negotiates Second Multibillion-Dollar Deal with Nscale for AI Infrastructure
- AI Infrastructure Stocks Drop Amid Inflation Concerns
- Troy Short Joins Nanoscope Therapeutics as Senior Vice President of Manufacturing and Supply Chain
- Investor Alert: Pomerantz Law Firm Investigates Novartis AG for Potential Securities Fraud
- PearX Demo Day Highlights Five Notable Startups
- Pfizer, Sanofi, and Novartis Highlight Key Healthcare News of the Week
- Big Pharma Companies Partner with Chinese Biotechs Amid Patent Expirations
- Novartis Enters Licensing Agreement with Abogen for RNA Therapeutics
- BoomRay Pharmaceuticals Enters into $900M Deal with Novartis for Radioligand Therapy
- Novartis Faces Another Pipeline Setback as ALS Drug Fails Mid-Stage Trial
- Morgan Stanley Highlights Amgen's Competitive Position After Novartis Heart Drug Trial Failure
- Novartis Suffers Third Drug Trial Setback in a Week and Faces Worst Trading Day in Years
- Novartis' Failed Cholesterol Drug Trial Raises Questions About Amgen and Eli Lilly's Experimental Treatments
- Amgen Stock Drops Sharply Amid Novartis' Lp(a)-Lowering Drug Failure
- Anthropic Establishes Biology Lab for AI-Driven Drug Research
- Novartis (NVS) and Ionis (IONS)' Experimental Cholesterol Drug Fails in Late-Stage Trial
- Novartis' Clinical Failure Impacts Cardiovascular Drug Race and Eli Lilly
- Monte Rosa Receives $50M Payment from Novartis for Phase 2 Trial Milestone
- Novartis' Pelacarsen Clinical Failure Impacts Cardiovascular Drug Race and Eli Lilly
- Amgen Shares Drop After Novartis' Lp(a)-Lowering Drug Fails in Trial
- Investors Scrutinize Novartis' M&A Strategy After Drug Trial Setbacks
- RA Capital's Investment Surge, Novartis' Clinical Trial Setbacks and Biotech Reverse Mergers
- BofA Sees Limited Impact from Novartis’ Pelacarsen Trial Failure, Citi Eyes Ionis
- Novartis Stock Drops After Key Drug Trial Failures
- Royalty Pharma's Pelacarsen Fails Phase 3 Trial; Focus Shifts to Spinraza Royalties
- Novartis Faces Setbacks in Key Drug Trials for Myotonic Dystrophy and Cholesterol
- Bristol-Myers Squibb Outperforms Novartis Amid CAR-T Safety Concerns and Strong Financial Momentum
- U.S. Stock Futures Drop as Oil Prices Rise Above $100 Amid U.S.-Iran Tensions
- Novartis Stock Drops After Key Drug Trial Failures
- Major Novartis Shareholder Calls for Board Changes After Drug Trial Setbacks
- Premarket Stock Movements: Macy's, Meta, Apple, Novartis and Others
- Stocks Decline on Rising Oil Prices and Ongoing Trade Tensions
- Dow Jones Falls Sharply Due to Novartis' Failed Drug Trials
- Novartis, Amgen Shares Drop After Disappointing Clinical Trial Results